Clinical Trials Browser

Phase 2 × disitamab vedotin × Gastrointestinal × Clear all

NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT07507526 2026-04-02

DTP-HER2

Phase 2 Not yet recruiting

Gastrointestinal

Gastric Adenocarcinoma

NCT06157892 2026-03-17

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Phase 2 Recruiting

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT05586061 2025-02-07

RCTS

Phase 2 Active not recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT06730373 2024-12-31

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06560528 2024-08-19

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06492317 2024-07-09

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Phase 2 Not yet recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT06385873 2024-05-13

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT06233864 2024-04-17

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06155383 2023-12-14

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05578287 2023-12-07

DETECT

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05627414 2022-11-25

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT05493683 2022-10-21

Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05333809 2022-04-20

Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms